BUSINESS

• Astellas Establishes “Regenerative Medicine Unit”; Aims to Establish Basic Technologies within 1 to 2 Years
  April 3, 2014

• 2014 Japan Debut of Prostate Cancer Drugs to End Dearth of CRPC Treatments
  April 2, 2014

• Latuda Granted European Regulatory Approval: DSP, Takeda
  April 2, 2014

• Abbott Japan Takes Over Marketing Approval for Duphaston from Daiichi Sankyo
  April 2, 2014

• Kyowa Kirin Files Nesp in Japan for Anemia in Myelodysplastic Syndrome
  April 2, 2014

• Japan Vaccine Files NDA for Pneumococcal Conjugate Vaccine in Japan
  April 2, 2014

• US Biotech NPS Takes Aim at Japan Debut around 2017
  April 1, 2014

• Torii Puts Off Launch of Sublingual Hay Fever Drug
  April 1, 2014

• Otsuka Acquires Rights for Dacogen from Eisai US Subsidiary
  April 1, 2014

• Shionogi Predicts Milder Patent Cliff for Crestor after AZ Deal: Pres.
  March 31, 2014

• AnGes MG to Procure 500 Million Yen through Allocation of New Shares to Third Party, to Invest in Orphan Drug Licensing
  March 31, 2014

• Suglat Tops February “Mind Share” Ranking in GP Market　
  March 31, 2014

• Uniform Pricing of Generics into 3 Price Brackets Will Make It More Difficult to Set Invoice Prices: Pres. Yoshiwaka of Daiichi Sankyo Espha
  March 28, 2014

• Takeda, Otsuka to Copromote Takeda’s Novel Acid-Related Disease Treatment Vonoprazan
  March 28, 2014

• Cetirizine Generics to Carry 3 Prices, Down from 13: Jiho Tally
  March 27, 2014

• Qualified Bidders Selected in 1st Qol-Led Open Tender
  March 27, 2014

• PII Study of Anti-PCSK9 Antibody in Japanese Patients Meets Primary Endpoint: Amgen Astellas
  March 27, 2014

• Major Generic Prices to Hover around 50% of Original Drug Prices in Their 1st Revision: Jiho
  March 26, 2014

• DSP’s Antipsychotic Agent Latuda Gets OK in Australia
  March 26, 2014

• MHLW Approves Toyama Chemical’s Novel Anti-Influenza Drug Avigan Tablets
  March 26, 2014

ページ

• « 先頭
• ‹ Prev
• …
• 551
• 552
• 553
• 554
• 555
• 556
• 557
• 558
• 559
• …
• Next ›
• 最終 »